Document is current
Any future updates will be listed below
-
Authors
Mimura, Hanaka https://orcid.org/0009-0006-9145-4332
Oura, Tomonori https://orcid.org/0000-0003-0872-8576
Chin, Rina https://orcid.org/0000-0001-5578-7814
Hirase, Tetsuaki https://orcid.org/0000-0003-1691-8003
Shimono, Dai
-
Clinical Trials BETA
Clinical trials referenced in this document:
nct03861052 at ClinicalTrials.govnct03861039 at ClinicalTrials.govDocuments that mention this clinical trial
Treatment Satisfaction and Quality of Life with Tirzepatide Versus Dulaglutide Among Japanese Patients with Type 2 Diabetes: Exploratory Evaluation of the SURPASS J-mono Trial
https://doi.org/10.1007/s13300-023-01485-3
Insulin Sensitivity and Beta-Cell Function Following Tirzepatide in Japanese Patients with Type 2 Diabetes: A SURPASS J-mono Analysis
https://doi.org/10.1007/s13300-025-01704-z
Metabolic Abnormalities Following Tirzepatide Monotherapy in Japanese Patients with Type 2 Diabetes: A Phase 3 SURPASS J-mono Post Hoc Analysis
https://doi.org/10.1007/s13300-024-01534-5
Association Between Early Weight Loss and Metabolic Outcomes with Tirzepatide in Japanese Patients with Type 2 Diabetes: A SURPASS J Post Hoc Analysis
https://doi.org/10.1007/s13300-025-01775-y
Documents that mention this clinical trial
Association Between Early Weight Loss and Metabolic Outcomes with Tirzepatide in Japanese Patients with Type 2 Diabetes: A SURPASS J Post Hoc Analysis
https://doi.org/10.1007/s13300-025-01775-y
-
Funding
Funding for this research was provided by:
Eli Lilly Japan
Mitsubishi Tanabe Pharma Corporation
- License Information
-
More Information
Article History
Received: 14 May 2025
Accepted: 18 July 2025
First Online: 25 July 2025
Declarations
:
: All authors declare funding support for this study and manuscript from Eli Lilly Japan K.K. and Mitsubishi Tanabe Pharma Corporation. Dai Shimono reports grants from Novo Nordisk Pharma and honoraria from Eli Lilly and Company and Mitsubishi Tanabe Pharma Corporation. Hanaka Mimura, Tomonori Oura, Rina Chin, and Tetsuaki Hirase are employees of Eli Lilly Japan and minor shareholders of Eli Lilly and Company.
: The SURPASS J study protocols were approved by independent ethical review boards at each study site (published in the primary manuscripts [, ]). The studies were conducted in accordance with the Declaration of Helsinki of 1964 (and its later amendments) and the Council for International Organizations of Medical Sciences International Ethical Guidelines. All participants provided written informed consent prior to study participation.
